API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/02/22/2833642/0/en/Salarius-Provides-Update-on-Strategic-Review-Process-and-Plans-to-Support-Ongoing-Seclidemstat-Clinical-Trials-by-Further-Reducing-Expenses.html
https://www.globenewswire.com//news-release/2024/01/03/2803302/0/en/Investigator-initiated-Phase-1-2-Clinical-Trial-Using-Salarius-Pharmaceuticals-Seclidemstat-in-Combination-with-Azacitidine-to-Treat-Hematologic-Cancers-Resumes-Patient-Enrollment.html
https://www.globenewswire.com//news-release/2023/11/07/2775117/0/en/Salarius-Completes-FDA-Type-B-Meeting-for-Seclidemstat-Ewing-Sarcoma-Development-Program.html
https://www.fiercebiotech.com/biotech/salarius-breaks-free-fda-hold-rare-cancer-trial-after-patient-death
https://www.globenewswire.com/news-release/2023/03/07/2621987/0/en/Salarius-Pharmaceuticals-to-Present-In-Vitro-Data-on-Seclidemstat-in-Small-Cell-Lung-Cancer-at-the-Keystone-Symposia.html
https://www.globenewswire.com/news-release/2022/12/13/2572708/0/en/Investigators-Present-Clinical-Data-on-Salarius-Pharmaceuticals-Seclidemstat-in-Patients-with-MDS-and-CMML-at-the-2022-American-Society-of-Hematology-Annual-Meeting.html
https://www.globenewswire.com//news-release/2022/12/01/2565893/0/en/Salarius-Pharmaceuticals-Announces-Interim-Results-from-Phase-1-2-Trial-of-Seclidemstat-as-a-Treatment-for-Ewing-Sarcoma-and-FET-Rearranged-Sarcomas.html
https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-announces-pause-new-patient-enrollment
https://www.globenewswire.com/news-release/2022/08/22/2502185/0/en/Salarius-Pharmaceuticals-Adds-Two-Mayo-Clinic-Sites-to-its-Ongoing-Phase-1-2-Trial-of-Seclidemstat-as-a-Treatment-for-Ewing-s-Sarcoma-and-FET-Rearranged-Sarcomas.html
https://www.globenewswire.com/news-release/2021/09/22/2301232/0/en/Salarius-Pharmaceuticals-and-Fox-Chase-Cancer-Center-Launch-Research-Partnership.html
https://www.globenewswire.com/news-release/2021/06/15/2247160/0/en/Salarius-Pharmaceuticals-Announces-New-Clinical-Trial-to-Study-Seclidemstat-in-Hematologic-Cancers.html
https://www.globenewswire.com/fr/news-release/2021/02/24/2181263/0/en/Salarius-Pharmaceuticals-Initiates-Expansion-Stage-of-Phase-1-2-Clinical-Trial-of-Seclidemstat-in-Patients-with-Ewing-Sarcoma-and-Ewing-Related-Sarcomas.html
https://www.globenewswire.com/news-release/2020/05/27/2039317/0/en/Salarius-Pharmaceuticals-to-Present-Trial-in-Progress-Poster-at-ASCO20-Virtual-Scientific-Program.html